Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Durand on Anthracyclines in Treatments for HER2+ Breast Cancer

March 16th 2018

Jean-Bernard Durand, MD, associate professor in the Department of Cardiology at The University of Texas MD Anderson Cancer Center, discusses protecting patients’ hearts from anthracyclines and HER2-targeted therapies when treating for HER2-positive breast cancer.

Dr. Brufsky on Challenges Facing Biosimilars in Breast Cancer

March 16th 2018

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, co-director, Comprehensive Breast Cancer Center, associate director, Clinical Investigation, University of Pittsburgh, discusses challenges facing biosimilars for the treatment of patients with breast cancer.

Acquired HER2 Mutations Cause Endocrine Resistance in ER+ Breast Cancer

March 15th 2018

Acquired HER2 mutations cause endocrine resistance in some patients with ER+/HER2-negative breast cancer.

HR-Positive Advances Highlight the Good News in Breast Cancer

March 15th 2018

Recent advancements in the field of breast cancer are reshaping the treatment paradigm for subsets of patients with the disease, bringing new therapies and strategies into focus.

Dr. Hurvitz Discusses De-Escalation in HER2+ Breast Cancer

March 15th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses de-escalation in HER2-positive breast cancer.

Taking a New Look at Primary Resection in Distant Metastatic Breast Cancer

March 14th 2018

The rate of resection of primary breast cancer in the setting of distant metastatic disease has fallen dramatically over the past decade, but results from recent studies may alter this trend.

Preventing Clinical Lymphedema With Bioimpedance Spectroscopy

March 14th 2018

Employing preclinical detection using bioimpedance spectroscopy, breast centers are reporting progression to clinical lymphedema in less than 10% of patients at high risk of developing the condition.

Hospitalists and Nonphysician Providers Can Step Into the Breach

March 14th 2018

Andrew Seidman, MD, focuses on his view of the increasing role of nurse practitioners in the outpatient setting and hospitalists in the inpatient setting.

Looking for a Therapeutic Edge Among CDK Inhibitors

March 13th 2018

Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.

Testing the Power of Neoadjuvant Systemic Therapy in Breast Cancer

March 13th 2018

Neoadjuvant therapy can eliminate both invasive and in situ carcinoma in up to 50% of patients, particularly when their subtypes are triple-negative disease or HER2-positive cancers.

Dr. Mittendorf on the Impact of Pertuzumab in HER2+ Breast Cancer

March 13th 2018

Elizabeth A. Mittendorf, MD, PhD, associate professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses the impact of pertuzumab (Perjeta) on the treatment landscape of HER2-positive breast cancer.

Abemaciclib Data Reviewed as New Breast Cancer Indications Added

March 12th 2018

Abemaciclib (Verzenio) has quickly amassed several clinical indications for patients with metastatic breast cancer, and is the only CDK4/6 inhibitor approved as a single agent.

Dr. Borgen on the Evolution of Breast Cancer Treatment

March 11th 2018

Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, and chair of the Miami Breast Cancer Conference, discusses the evolution of breast cancer treatment in recent years. Borgen shared his insight in an interview during the meeting.

Neoadjuvant Endocrine Therapy Ideal for Some Breast Cancer Patients

March 11th 2018

Endocrine therapy can achieve tumor reduction for patients with ER-positive breast cancer, possibly avoiding the need for chemotherapy or even surgery in some patients; however, deciding how long to continue this therapy can be tricky.

AJCC Staging Manual Gives Boost to Precision Medicine

March 11th 2018

The latest revision of the staging manual for breast cancer from the American Joint Committee on Cancer is a quantum leap toward precision oncology, as it codifies advanced knowledge of the role of biologic factors in cancer, and oncologists should now be using it.

PARP Inhibitors Arrive for BRCA+ Breast Cancer

March 11th 2018

The PARP inhibitors have finally become available for patients with BRCA-mutant metastatic breast cancer, ushering in a potential new era for targeted therapies with studies currently ongoing in the adjuvant setting and exploring combinations.

Dual Targeting Advances in HER2+/HR+ Breast Cancer

March 11th 2018

The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.

Hurvitz Heralds Next HER2+ Breast Cancer Breakthroughs

March 10th 2018

Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.

Dr. King Discusses Approaches to Lymphedema in Breast Cancer

March 10th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses approaches to treating lymphedema in patients with breast cancer.

Dr. Robson on Exploratory Analysis From OlympiAD in Breast Cancer

March 9th 2018

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses an exploratory analysis of the OlympiAD trial for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.